Vimpat Data will be Presented at AES Annual Meeting

UCB, a leading biopharmaceutical company, is committed to helping develop new treatments for epilepsy. The company is sponsoring several key sets of Vimpat (also known as lacosamide) C-V information at this year’s Annual Meeting of the American Epilepsy Society (AES) in Baltimore on December 2-6.

“At UCB, we are committed to working toward improving the lives of people living with epilepsy,” Dr. James Zackheim, senior medical director, Central Nervous System Business Unit, UCB Inc., says. “Therefore, we believe it is vitally important to invest in research to better understand the clinical profile of Vimpat.”

The drug Vimpat is considered an additional therapy for use in the treatment of partial-onset seizures in adults with epilepsy. So far, the most commonly known side effects that have been reported include dizziness, headache and nausea. That is a far cry from the adverse side effects currently associated with other anti-seizure medications like Topamax. Topamax, made by drug giant Johnson & Johnson, has come under fire for causing birth defects in babies whose mothers take the drug while pregnant. Some of those birth defect include PPHN, neural tube defects, cleft palate and heart, and brain defects.

Even though Topamax has been linked to such serious side effects for babies, doctors continue to prescribe it. Some patients are even developing glaucoma after taking the drug. With so many harmful side effects, thousands of patients are filing lawsuits against J&J amid claims that the company didn’t properly warn the public of the side effects before putting it on the market.

If your baby was born with birth defects after taking Topamax, contact attorney Greg Jones today for a free consultation. I am experienced at fighting Topamax lawsuits, and I will work hard to get you any money that you may be entitled to for your baby’s injuries.

Tags:
Share this article

You May Also Like

All Rights Reserved 2016